Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Anson

<< Previous

Bullboard Posts

Next >>

Comment by Peladawnon Nov 14, 2023 3:05pm

123 Views

Post# 35735133

RE:Anson

Cmon boost!....not you now too!.....why on God’s green earth would Pancan step aside because they found out Anson was financing?......cmon man....stay real.....and again.....they did not step aside....they stated plainly that they decided to re-evaluate their own program...they did NOT decide to re-evaluate oncy’s program or Santa’s program....and they are still full on with the Collorectal arm. Geez!....people!.....get a grip!u

<< Previous

Bullboard Posts

Next >>

High-growth stock Happy Belly opens first Rosie's Burgers in Alberta